Literature DB >> 9243620

Fast transport and retrograde movement of huntingtin and HAP 1 in axons.

J Block-Galarza1, K O Chase, E Sapp, K T Vaughn, R B Vallee, M DiFiglia, N Aronin.   

Abstract

Huntingtin, the protein product of the Huntington's disease gene, associates with vesicle membranes and microtubules in neurons. Analysis of axonal transport with a stop-flow, double crush ligation approach in rat sciatic nerve showed that full length huntingtin (350 kDa) and an N-terminal cleavage product (50 kD) were increased within 6-12 h on both the proximal and distal sides of the crush site when compared with normal unligated nerve. The huntingtin associated protein HAP 1 and the retrograde motor protein dynein also accumulated on both sides of the crush, whereas the vesicle docking protein SNAP-25 was elevated only proximally. The cytoskeletal protein alpha-tubulin was unaffected. The rapid anterograde accumulation of huntingtin and HAP 1 is compatible with their axonal transport on vesicular membranes. Retrograde movement of both proteins, as seen by accumulation distal to the nerve crush, may be necessary for their degradation at the soma or for a function in retrograde membrane trafficking.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9243620     DOI: 10.1097/00001756-199707070-00031

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  36 in total

Review 1.  Polyglutamine pathogenesis.

Authors:  C A Ross; J D Wood; G Schilling; M F Peters; F C Nucifora; J K Cooper; A H Sharp; R L Margolis; D R Borchelt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 2.  The localization and interactions of huntingtin.

Authors:  A L Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

3.  Modeling Huntington's disease in cells, flies, and mice.

Authors:  S Sipione; E Cattaneo
Journal:  Mol Neurobiol       Date:  2001-02       Impact factor: 5.590

4.  The role of post-translational modifications of huntingtin in the pathogenesis of Huntington's disease.

Authors:  Yan Wang; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-04       Impact factor: 5.203

Review 5.  Oligonucleotide therapeutic approaches for Huntington disease.

Authors:  Dinah W Y Sah; Neil Aronin
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

6.  A C. elegans homolog of huntingtin-associated protein 1 is expressed in chemosensory neurons and in a number of other somatic cell types.

Authors:  Kristina B Mercer; Sarah M Szlam; Erin Manning; Kim M Gernert; Walter W Walthall; Guy M Benian; Claire-Anne Gutekunst
Journal:  J Mol Neurosci       Date:  2008-07-01       Impact factor: 3.444

7.  Mass spectrometric identification of novel lysine acetylation sites in huntingtin.

Authors:  Xin Cong; Jason M Held; Francesco DeGiacomo; Akilah Bonner; Jan Marie Chen; Birgit Schilling; Gregg A Czerwieniec; Bradford W Gibson; Lisa M Ellerby
Journal:  Mol Cell Proteomics       Date:  2011-06-18       Impact factor: 5.911

Review 8.  Dynein activators and adaptors at a glance.

Authors:  Mara A Olenick; Erika L F Holzbaur
Journal:  J Cell Sci       Date:  2019-03-15       Impact factor: 5.285

9.  Huntingtin regulates RE1-silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) nuclear trafficking indirectly through a complex with REST/NRSF-interacting LIM domain protein (RILP) and dynactin p150 Glued.

Authors:  Masahito Shimojo
Journal:  J Biol Chem       Date:  2008-10-15       Impact factor: 5.157

Review 10.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.